Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 26, 2013BloodOpen Access

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

View Full Paper
Ask AI
Bookmark
Share

Authors

VSValeria SantiniJSJennifer SchemenauALAlessandro Levis

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Santini et al. (2013) studied this question.

synapsesocial.com/papers/6a20d73b34bef10fdaeb0d67https://doi.org/10.1182/blood-2013-07-512442
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge2012 · 695 citations
  2. 2Revised International Prognostic Scoring System for Myelodysplastic Syndromes2012 · 3,196 citations
  3. 3International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes1997 · 4,480 citations
  4. 4A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life2003 · 456 citations